Cidara Therapeutics Inc (NASDAQ: CDTX) is -19.27% lower on its value in year-to-date trading and has touched a low of $10.00 and a high of $28.42 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CDTX stock was last observed hovering at around $21.25 in the last trading session, with the day’s gains setting it 0.45%.
Currently trading at $21.70, the stock is -8.48% and 6.76% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.23 million and changing 2.12% at the moment leaves the stock 50.08% off its SMA200. CDTX registered 52.39% gain for a year compared to 6-month gain of 71.68%. The firm has a 50-day simple moving average (SMA 50) of $20.3264 and a 200-day simple moving average (SMA200) of $14.45922.
The stock witnessed a -6.71% loss in the last 1 month and extending the period to 3 months gives it a 102.05%, and is -9.58% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.34% over the week and 10.60% over the month.
Cidara Therapeutics Inc (CDTX) has around 69 employees, a market worth around $237.51M and $26.35M in sales. Profit margin for the company is -460.50%. Distance from 52-week low is 116.91% and -23.65% from its 52-week high. The company has generated returns on investments over the last 12 months (-102.83%).
with sales reaching $300k over the same period.The EPS is expected to shrink by -358.21% this year, but quarterly earnings will post -91.65% year-over-year. Quarterly sales are estimated to shrink -98.29% in year-over-year returns.
Cidara Therapeutics Inc (CDTX) Top Institutional Holders
33.0 institutions hold shares in Cidara Therapeutics Inc (CDTX), with institutional investors hold 54.43% of the company’s shares. The shares outstanding are 7.05M, and float is at 4.66M with Short Float at 1.66%. Institutions hold 51.86% of the Float.
The top institutional shareholder in the company is WETZEL INVESTMENT ADVISORS, INC. with over 4000.0 shares valued at $3680.0. The investor’s holdings represent 0.0881% of the CDTX Shares outstanding.
Cidara Therapeutics Inc (CDTX) Insider Activity
The most recent transaction is an insider sale by Sandison Taylor, the company’s Chief Medical Officer. SEC filings show that Sandison Taylor sold 924 shares of the company’s common stock on Sep 11 ’24 at a price of $11.64 per share for a total of $10752.0. Following the sale, the insider now owns 23067.0 shares.
Cidara Therapeutics Inc disclosed in a document filed with the SEC on Sep 11 ’24 that Tari Leslie (CHIEF SCIENTIFIC OFFICER) sold a total of 909 shares of the company’s common stock. The trade occurred on Sep 11 ’24 and was made at $11.64 per share for $10580.0. Following the transaction, the insider now directly holds 17788.0 shares of the CDTX stock.
Still, SEC filings show that on Jun 07 ’24, Stein Jeffrey (President & CEO) acquired 8,000 shares at an average price of $13.21 for $0.11 million. The insider now directly holds 24,580 shares of Cidara Therapeutics Inc (CDTX).
